17607-81-7

Basic information

• Product Name: 1H-Pyrazole-3-carboxylic acid, 5-methyl-1-(phenylmethyl)-, ethyl ester
• Synonyms: Ethyl 1-benzyl-5-methyl-1H-pyrazole-3-carboxylate
• CAS NO: 17607-81-7
• Molecular Formula: C₁₄H₁₆N₂O₂
• Molecular Weight: 244.293
• Mol File: 17607-81-7.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 389.4 °C at 760 mmHg
• Flash Point: 189.3 °C
• Density: 1.11 g/cm³
• CAS DataBase Reference: 1H-Pyrazole-3-carboxylic acid, 5-methyl-1-(phenylmethyl)-, ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Pyrazole-3-carboxylic acid, 5-methyl-1-(phenylmethyl)-, ethyl ester(17607-81-7)
• EPA Substance Registry System: 1H-Pyrazole-3-carboxylic acid, 5-methyl-1-(phenylmethyl)-, ethyl ester(17607-81-7)

Safety Data

• Hazardous Substances Data: 17607-81-7(Hazardous Substances Data)

Usage

Structure

Ethyl ester derivative of 1H-pyrazole-3-carboxylic acid with a substituent of 5-methyl-1-(phenylmethyl)-

Usage

Building block in the synthesis of pharmaceuticals and agrochemicals, potential therapeutic properties, valuable tool in medicinal chemistry and drug discovery.

Upstream product

• 615-79-2 ethyl 2,4-diketopentanoate 
• 555-96-4 Benzylhydrazine 
• 20570-96-1 benzylhydrazine dihydrochloride 
• 100-39-0 benzyl bromide 
• 4027-57-0 ethyl 5-methyl-2H-pyrazole-3-carboxylate 
• 100-44-7 benzyl chloride 

Downstream Products

• 17607-80-6 1-benzyl-5-methyl-1H-pyrazole-3-carboxylic acid 
• 1141-70-4 1-benzyl-3-methyl-1H-pyrazole-5-carboxylic acid 

Relevant articles and documents

Novel Compounds

The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C- terminal hydrolase 30 or Ubiquitin Specific Peptidase 30 (USP30). The invention further relates to the use of DUB inhibitors in the treatment of conditions involving mitochondrial dysfunction and cancer. Compounds of the invention include compounds having the formula (I): (I) or a pharmaceutically acceptable salt thereof, wherein R1a, R1b, R1c, R1d, R1e, R1f, R1g, R2, X, L and A are as defined herein.

Monocyclic heterocycles as kinase inhibitors

The present invention is directed to compounds having the formula and methods for using them for the treatment of cancer.

Orientation de la reaction d'alkylation des pyrazoles dans des conditions neutres et en catalyse par transfert de phase

The N-butylation and N-benzylation of nine pyrazoles bearing different substituents in positions 3 and 5 have been studied in neutral and basic medium (phase transfer catalysis).The orientation of the reaction depends strongly on the method used when the